Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 8/20 | 0.51 |
| ▸ | CALCR | P30988 | 8/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CCKAR | P32238 | 1/20 | 0.43 |
| ▸ | CCKBR | P32239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12984108 | 0.83 | RAMP3 (0.62) | RAMP3CALCR | |
| SCHEMBL10065572 | 0.80 | PRSS1 (0.48) | RAMP3CALCRFOLH1F2PLG | |
| SCHEMBL12984646 | 0.79 | RAMP3 (0.63) | RAMP3CALCR | |
| SCHEMBL26004079 | 0.78 | APLNR (0.57) | F2PLGPRSS1PRSS2PRSS3 | |
| SCHEMBL10066201 | 0.77 | PRSS1 (0.49) | RAMP3CALCRFOLH1F2PLG | |
| SCHEMBL10065714 | 0.77 | PRSS1 (0.50) | RAMP3CALCRFOLH1F2PLG | |
| SCHEMBL12984654 | 0.76 | PKM (0.49) | FOLH1F2PLGPRSS1PRSS2 | |
| SCHEMBL10065813 | 0.76 | PRSS1 (0.47) | FOLH1F2PLGPRSS1PRSS2 | |
| SCHEMBL17209386 | 0.75 | FOLH1 (0.52) | FOLH1F2PLGPRSS1PRSS2 | |
| SCHEMBL12429627 | 0.75 | FOLH1 (0.52) | FOLH1F2PLGPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165211-A1 | Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques | BRACCO IMAGING S.P.A. (IT) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165211-A1 | Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques | TAGLN2, TTN, TXLNA | RAMP3 2430/4885CALCR 2408/4885FOLH1 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.